FENTORA (fentanyl citrate) by Teva is analgesia. First approved in 2006.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
FENTORA (fentanyl citrate) is a potent opioid analgesic delivered via buccal or sublingual tablet for rapid onset pain relief. It works through mu-opioid receptor agonism to produce analgesia. The product is indicated for opioid-tolerant patients requiring breakthrough pain management.
Shrinking revenue base with 2 years to LOE signals transition planning and potential team consolidation or redeployment.
analgesia.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
Worked on FENTORA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Working on FENTORA presents a challenging career scenario: minimal linked job openings and declining market presence limit growth opportunities. This role is best suited for professionals managing portfolio transition, legacy products, or preparing for role redeployment post-LOE.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo